Markets · bedrock market · provisional

EU Centrally Authorised Medicines (EMA marketing-authorisation holders)

Regulated market (ema centrally authorised medicines, ma holders). The Kin Score Market layer reads each provider in its market: who it integrates with, how deep those integrations go, and where the market publishes its own structure. Methodology.

19providers measured
0 (0.0%)declare their own
0 (0.0%)covered by others only
19 (100.0%)undeclared
0in-market workflows shown
Provisional. Provisional and unweighted: the Market layer is not part of the composite or agent readiness. Leader lists are read within a position, never as one ranking. A provider that declares nothing we can read is shown as undeclared, with no number: we never infer integrations.

Where this market publishes its structure

Own = declares at least one integration itself; covered = visible only because an aggregator, standards body, regulator or partner contract names it; distribution-only = listed only on cloud marketplaces it sells through, a channel reported beside, never counted as its own declared integrations; undeclared = nothing we can read, so no number; declares_compatibility = providers with a `compatible` shape vote, report only (kin, 2026-10-13): never counted as own, never in depth or position.

Taxonomy how this market maps onto apis.io

Derived 2026-10-23 from the 19 providers in this market we could resolve in the catalog. The percentage is the share of those providers carrying each one; it describes the market, not the tag or industry. Tag groups have no page of their own yet, so they are listed unlinked.

TagsHealthcare 84%, Pharmaceuticals 84%, Biotechnology 58%, Life Sciences 58%, Fortune 500 37%, Clinical Trials 26%
Tag groupsHealthcare 95%
IndustriesHealthcare 89%, Pharmaceutical 89%, Biotechnology & Drug Discovery 63%, Life Sciences 58%

share of resolved cohort carrying it; tags >=0.20 & >=3 members (max 12, junk dropped), tag_groups >=0.20 (cooccurrence, non-cross-cutting; max 8), industries >=0.20 (max 6), areas >=0.10 (max 6; areas are keyword-matched and sparse), capabilities L1 >=0.20 (max 8); derive-market-taxonomy.py

Leaders by position (provisional)

Provisional: grouped by position, depth compared within a position only. Distribution (cloud marketplaces) and iPaaS bridges are counted beside position, never inside it. Unknown-builder listings are left out of position shares and counted here.

undeclared 19 · declares nothing we can read: no number

ProviderDepthIntegrationsIn / outUnknown builderDistributioniPaaS bridgeMix
Abbott Laboratories undeclared-----
AbbVie undeclared-----
AstraZeneca undeclared-----
Autolus undeclared-----
Bayer undeclared-----
Biogen undeclared-----
Eli Lilly undeclared-----
Gilead Sciences undeclared-----
GSK undeclared-----
Insmed undeclared-----
Merck undeclared-----
Novartis undeclared-----
Novo Nordisk undeclared-----
Organon undeclared-----
Pfizer undeclared-----
Sanofi undeclared-----
Takeda Pharmaceutical Company undeclared-----
Vertex Pharmaceuticals undeclared-----
Viatris undeclared-----

Generated 2026-10-23 from API Evangelist's own files; nothing on this page is a model's judgement. Provisional and unweighted; not part of the Kin Score composite or agent readiness. Read the Market layer methodology. Disagree with an edge? Every edge cites its evidence and can be corrected through the normal correction path.